Kaplan Fox Encourages Investors of Microvast Holdings, Inc. (NASDAQ: MVST) to Contact the Firm to Learn About Their Legal Rights

A securities class action alleges Microvast misled investors about its Huzhou Phase 3.2 production expansion and its ability to achieve margin targets during April 1, 2025 to March 16, 2026. The complaint cites Microvast's Q4 2025 gross margin collapse to approximately 1% from approximately 36% a year earlier, alongside a 15% year-over-year revenue decline to $96.5 million. The company attributed the deterioration to inventory impairment charges, South Korean regulatory shifts and delayed customer platform ramp-ups; investors have until September 21, 2026 to seek lead-plaintiff status.

Analysis

The actionable issue is not the litigation notice itself—these filings rarely create incremental fundamental information—but whether the underlying inventory write-down signals a recurring failure in product qualification, demand forecasting, or customer-concentration management. For MVST, a near-breakeven gross-margin quarter implies that relatively modest further impairments, warranty costs, or under-absorption at manufacturing sites could require additional working-capital funding. That creates a 6-18 month downside asymmetry: a capital raise or prolonged low utilization would pressure both equity value and the credibility of any capacity-led growth narrative.

The key 1-3 month catalyst path is management's next update on inventory normalization, operating cash burn, customer ramp timing, and capital-expenditure commitments. A recovery case requires evidence that impaired inventory was isolated, not evidence of merely improved reported revenue; gross margin should recover materially while receivables and inventory decline sequentially. If margins remain below the mid-teens despite higher utilization, the market should treat the issue as structural pricing/product-mix weakness rather than a one-time accounting event.

Competitive read-through is limited. Battery and energy-storage peers such as FLNC, STEM, and ENS should not be sold on this news absent evidence of broader ESS component obsolescence or delayed commercial deployments, since MVST-specific execution and customer timing appear more relevant than an industry demand reset. BAC has no investable linkage to this development.

Contrarianly, the stock may already embed substantial distress and litigation risk; therefore, shorting after legal headlines alone has poor expected value if borrow is expensive or the float is constrained. The more attractive bearish setup would be a failed operational recovery—another inventory charge, weak cash conversion, or reduced forward margin guidance—rather than the lawsuit process.

Key Decisions for Investors

• Do not initiate a position solely on the class-action announcement; treat it as a governance/liquidity watch item rather than a new fundamental catalyst.
• Maintain or initiate a small MVST short only following a failed next-quarter validation: gross margin below 15%, inventory rising sequentially, or operating cash burn worsening despite revenue growth. Size for high volatility and cover if management demonstrates two consecutive quarters of margin recovery with declining inventory.
• For existing MVST longs, require a defined 1-2 quarter recovery checklist: sequential inventory reduction, stable customer ramp schedules, and cash runway sufficient to avoid near-term dilution. Absent those markers, reduce exposure rather than averaging down.
• Monitor securities-lending availability and borrow cost before any bearish trade. If borrow becomes punitive or short interest rises sharply without new operational deterioration, avoid the short; a squeeze can dominate the litigation-driven price signal.